CHANTIX® (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX

Thu Jan 24, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130124:nBw245095a

New Positive Top-line Results in Adult Smokers Re-treated With CHANTIX
NEW YORK--(Business Wire)--
Pfizer Inc. (NYSE: PFE) announced today that a post-marketing study assessing
the efficacy and safety of varenicline (CHANTIX®/CHAMPIX®) in a population of
smokers who had made a previous attempt to quit smoking with CHANTIX, and either
did not succeed in quitting or relapsed after treatment, met its primary
endpoint. 

CHANTIX significantly increased continuous abstinence rates compared to placebo
at weeks nine to 12, the last four weeks of treatment (primary endpoint). The
efficacy rates were consistent with findings seen in other CHANTIX clinical
trials in smokers who had not been previously treated with CHANTIX. The safety
and tolerability profile of CHANTIX in this study was also consistent with
previous studies. The most commonly reported treatment-emergent adverse events
were nausea, abnormal dreams and headache, with incidence rates similar to
previous CHANTIX studies. 

"Smoking is considered a chronic, relapsing medical condition. The availability
of pharmacological treatments has led to a large and growing population of
smokers who have made previous quit attempts but were ultimately unsuccessful,"
said Steven J. Romano, M.D., senior vice president and medicines development
group head, Primary Care Business Unit, Pfizer Inc. "These new data show that,
for some adult smokers who had previously taken CHANTIX but either did not quit
smoking or relapsed after quitting, another quit attempt with CHANTIX may be
fruitful." 

Study Background

This study was a Phase 4, 12-week, randomized, double-blind, placebo-controlled,
multi-center study, which evaluated the efficacy and safety of varenicline
tartrate 1 mg BID for smoking cessation in adult subjects, who had made a
previous attempt to quit smoking with CHANTIX and either did not succeed in
quitting or relapsed after treatment. Patients included in this study had taken
CHANTIX for a smoking-cessation attempt in the past (for a total treatment
duration of a minimum of two weeks), and at least three months prior to study
entry, and had been smoking for at least four weeks. 

About CHANTIX

CHANTIX was approved by the FDA in May 2006 as an aid to smoking cessation
treatment in adults 18 and older. CHANTIX has been shown to increase the
likelihood of abstinence from smoking for as long as one year compared to
treatment with placebo. Adults who smoke may benefit from quit smoking support
programs and/or counseling during their quit attempt. It`s possible that
patients might slip up and smoke while taking CHANTIX. If patients slip up, they
can stay on CHANTIX and keep trying to quit. 

Important CHANTIX (varenicline) Safety Information

Some people have had changes in behavior, hostility, agitation, depressed mood,
suicidal thoughts or actions while using CHANTIX to help them quit smoking.Some
people had these symptoms when they began taking CHANTIX, and others developed
them after several weeks of treatment or after stopping CHANTIX. If the CHANTIX
patient, their family or caregiver notice any of these symptoms or behaviors,
they should stop taking CHANTIX and call their doctor right away.They should
tell their doctor about any history of depression or other mental health
problems, which could get worse while taking CHANTIX.

Patients should not take CHANTIX if they`ve had a serious allergic or skin
reaction to it. If they develop serious allergic or skin reactions, including
swelling of the face, mouth, throat, or a rash, they should stop taking CHANTIX
and see their doctor right away as some of these can be life-threatening. 

Patients should tell their doctor if they have a history of heart or blood
vessel problems or have any new or worse symptoms during treatment with CHANTIX.
Patients should get emergency medical help right away if they have any symptoms
of a heart attack or stroke. 

Dosing may be different for patients who have kidney problems. Until the patient
knows how CHANTIX affects them, they should use caution when driving or
operation machinery. Common side effects include nausea, trouble sleeping and
unusual dreams. CHANTIX should not be taken with other quit-smoking products.
Patients should tell their doctor which medicines they are taking as these
medicines may work differently when quitting smoking. 

Full prescribing information and Medication Guide are available at
www.pfizer.com. 

Pfizer Inc.: Working together for a healthier world

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines; as well as
many of the world`s best-known consumer products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness, prevention,
treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as the world`s leading biopharmaceutical
company, we also collaborate with health care providers, governments and local
communities to support and expand access to reliable, affordable health care
around the world. For more than 150 years, Pfizer has worked to make a
difference for all who rely on us. 

Varenicline is known as CHANTIX® in the U.S. and CHAMPIX® outside the U.S.

Pfizer Inc.
Media Contact:
Jennifer Kokell, 212-733-2596
Jennifer.Kokell@pfizer.com
or
Investor Contact:
Suzanne Harnett, 212-733-8009
Suzanne.Harnett@pfizer.com



Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.